Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from SciSparc Ltd. ( (SPRC) ).
SciSparc Ltd. and Clearmind Medicine Inc. have announced the publication of a European patent application for a combination therapy targeting binge behaviors, including alcohol and tobacco consumption. This collaboration leverages psychedelic molecules with N-acylethanolamines and has led to the filing of thirteen patents globally. This announcement strengthens SciSparc’s position in the pharmaceutical industry, enhancing their innovation in developing treatments for central nervous system disorders and potentially widening their market reach.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders using cannabinoid pharmaceuticals. Their drug development programs focus on treatments for conditions like Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. Additionally, they have a subsidiary that sells hemp seed oil products on Amazon.
YTD Price Performance: 34.44%
Average Trading Volume: 4,864,603
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.47M
For a thorough assessment of SPRC stock, go to TipRanks’ Stock Analysis page.
